ARTIVION, INC. (AORT)

What does Artivion actually make?

Artivion designs and sells medical devices and preserved biological tissues used by cardiac and vascular surgeons to repair aortic diseases. The company’s core portfolio spans four areas: aortic stent grafts (devices that reinforce weak sections of the aorta from inside), On-X mechanical heart valves (prosthetic replacements), surgical sealants and biological glues for cardiac surgery, and preserved human heart and blood vessel tissues for transplant and reconstruction. The business splits into two operating segments—Medical Devices and Preservation Services—and reaches surgeons and hospitals across more than 100 countries.

Where’s the revenue coming from?

The Medical Devices segment drives most income through the sale of stent grafts, mechanical valves, sealants, and synthetic grafts to hospitals and surgical centers worldwide. Preservation Services supplies preserved cardiac and vascular tissues—largely allografts and xenografts—for use in surgery and transplantation. Both segments serve the same customer base of surgeons and interventional specialists, creating cross-sell and bundling opportunities within the operating room.

What’s Artivion’s competitive position in aortic surgery?

Artivion competes in a specialized corner of the broader medical device industry, where competitors include other device makers and tissue banks. The company has built a long-standing partnership and supplier relationship with Endospan Ltd., a developer of endovascular solutions for aortic arch disease. In May 2026, Artivion completed its acquisition of Endospan, incorporating Endospan’s FDA-approved NEXUS Aortic Arch System into Artivion’s lineup and deepening its presence in the growing minimally invasive aortic repair market.

How does Artivion’s scale compare to larger device makers?

Artivion operates with over 1,250 employees and a global footprint across more than 100 countries. While smaller than diversified giants like Medtronic or Boston Scientific, the company occupies a focused niche in cardiac and aortic surgery. Its targeted product mix—rather than breadth across dozens of specialties—reflects a strategy of depth in one high-stakes surgical domain.

What drives demand for these products?

Aging populations in developed markets experience rising rates of aortic disease, aneurysm, and valve dysfunction, creating steady demand for repair devices and tissue. Minimally invasive techniques and endovascular solutions (like the newly acquired NEXUS system) are gradually replacing or supplementing traditional open surgical approaches, opening new market segments. Surgeons’ need for reliable sealants, grafts, and preserved tissues in operating rooms, wherever patients are treated, sustains recurring revenue.